Otten TM - Search Results

1

Forecasting the value of innovation in total knee arthroplasty care: A headroom approach.

Otten TM, Grimm SE, Ramaekers B, Roth A, Emans P, Boymans T, Janssen M, Jeuken R, Joore MA. Otten TM, et al. J Exp Orthop. 2024 Dec 18;11(4):e70096. doi: 10.1002/jeo2.70096. eCollection 2024 Oct. J Exp Orthop. 2024. PMID: 39697990 Free PMC article.

2

Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations.

Otten TM, Grimm SE, Ramaekers B, Joore MA. Otten TM, et al. Pharmacoeconomics. 2023 Jun;41(6):619-632. doi: 10.1007/s40273-023-01242-1. Epub 2023 Mar 21. Pharmacoeconomics. 2023. PMID: 36943674 Free PMC article. Review.

3

State of the ART? Two New Tools for Risk Communication in Health Technology Assessments.

Grimm SE, Pouwels X, Ramaekers BLT, Wijnen B, Otten T, Grutters J, Joore MA. Grimm SE, et al. Pharmacoeconomics. 2021 Oct;39(10):1185-1196. doi: 10.1007/s40273-021-01060-3. Epub 2021 Jul 19. Pharmacoeconomics. 2021. PMID: 34278550 Free PMC article.

4

Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Otten T, Riemsma R, Wijnen B, Armstrong N, Stirk L, Gordon C, Ramaekers B, Kleijnen J, Joore M, Grimm S. Otten T, et al. Pharmacoeconomics. 2022 Sep;40(9):851-861. doi: 10.1007/s40273-022-01166-2. Epub 2022 Jul 8. Pharmacoeconomics. 2022. PMID: 35802295 Free PMC article. Review.

5

Correction: Belimumab for Treating Active Autoantibody‑Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Otten T, Riemsma R, Wijnen B, Armstrong N, Stirk L, Gordon C, Ramaekers B, Kleijnen J, Joore M, Grimm S. Otten T, et al. Pharmacoeconomics. 2023 Nov;41(11):1551. doi: 10.1007/s40273-023-01315-1. Pharmacoeconomics. 2023. PMID: 37665503 Free PMC article. No abstract available.

6

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Wijnen B, Witlox W, Wolff R, Fayter D, Ramaekers B, Otten T, Ryder S, Posadzki P, Worthy G, Stirk L, Armstrong N, Kleijnen J, Joore M. Wijnen B, et al. Pharmacoeconomics. 2023 Jan;41(1):33-42. doi: 10.1007/s40273-022-01209-8. Epub 2022 Oct 27. Pharmacoeconomics. 2023. PMID: 36301414 Free PMC article. Review.

7

Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Witlox W, Grimm S, Howick J, Armstrong N, Ahmadu C, McDermott K, Otten T, Noake C, Wolff R, Joore M. Witlox W, et al. Pharmacoeconomics. 2023 Aug;41(8):857-867. doi: 10.1007/s40273-023-01272-9. Epub 2023 May 2. Pharmacoeconomics. 2023. PMID: 37129774 Free PMC article. Review.

8

Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective.

Sugden BM, Grimm SE, Wolff R, Armstrong N, Otten T, Abu-Zahra T, Perry M, Patel M, Chen J, Noake C, Joore M, Witlox WJA. Sugden BM, et al. Pharmacoeconomics. 2024 Jun;42(6):615-618. doi: 10.1007/s40273-024-01381-z. Epub 2024 May 7. Pharmacoeconomics. 2024. PMID: 38713424 Free PMC article. No abstract available.

9

Headroom Analysis for Early Economic Evaluation: A Systematic Review.

Boudewijns EA, Otten TM, Gobianidze M, Ramaekers BL, van Schayck OCP, Joore MA. Boudewijns EA, et al. Among authors: otten tm. Appl Health Econ Health Policy. 2023 Mar;21(2):195-204. doi: 10.1007/s40258-022-00774-5. Epub 2022 Dec 28. Appl Health Econ Health Policy. 2023. PMID: 36575333

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters